Zydus Life Sciences Stock Analysis: Undervalued or Overlooked?
We recently discussed a company. on our YouTube channel, with a market capitalisation of over ₹1,10,000 crore that earns close to half of its revenue from the United States, and whose stock spent the better part of 18–20 months going nowhere. On a price-to-earnings basis it had drifted down to a meaningful discount to its […]